Dermira Inc. (DERM) Lifted to “Hold” at Zacks Investment Research
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
DERM has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a positive rating and issued a $46.00 price target on shares of Dermira in a report on Monday, October 3rd. Leerink Swann reissued a buy rating on shares of Dermira in a report on Wednesday, October 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Dermira has an average rating of Buy and a consensus price target of $41.00.
Dermira (NASDAQ:DERM) opened at 32.72 on Thursday. Dermira has a 52 week low of $17.42 and a 52 week high of $36.34. The stock has a 50 day moving average price of $32.82 and a 200-day moving average price of $31.93. The company’s market capitalization is $1.16 billion.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.72) EPS for the quarter, hitting analysts’ consensus estimates of ($0.72). On average, equities analysts predict that Dermira will post ($3.32) earnings per share for the current fiscal year.
In other news, CEO Thomas G. Wiggans sold 11,000 shares of the business’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $31.63, for a total transaction of $347,930.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 4,100 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $35.02, for a total transaction of $143,582.00. Following the transaction, the chief financial officer now owns 9,216 shares of the company’s stock, valued at $322,744.32. The disclosure for this sale can be found here. Company insiders own 17.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its position in Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock worth $118,847,000 after buying an additional 921,800 shares during the period. Jennison Associates LLC raised its position in Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock worth $73,539,000 after buying an additional 860,597 shares during the period. TimesSquare Capital Management LLC raised its position in Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock worth $72,877,000 after buying an additional 1,101,645 shares during the period. Eagle Asset Management Inc. raised its position in Dermira by 4.3% in the second quarter. Eagle Asset Management Inc. now owns 1,344,721 shares of the biopharmaceutical company’s stock worth $39,333,000 after buying an additional 55,991 shares during the period. Finally, BlackRock Fund Advisors raised its position in Dermira by 10.8% in the third quarter. BlackRock Fund Advisors now owns 1,325,981 shares of the biopharmaceutical company’s stock worth $44,845,000 after buying an additional 129,437 shares during the period. Hedge funds and other institutional investors own 84.95% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.